Index

Note: Page numbers of article titles are in boldface type.

A
Activated partial thromboplastin time, for anticoagulant monitoring, 764–765
Acurate valve, 829
Acute coronary syndrome, 835–847
   clinical findings in, 840–842
   history in, 838–840
   imaging for, 842–844
   pathophysiology of, 836–838
   physical examination for, 838–840
   statistics on, 835–836
   testing for, 842–844
   versus noncardiac pain, 839, 841
Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (APEX), 765, 774–775
ADVANCE registry, for TAVR, 818, 820
AFFIRM trial, for atrial fibrillation, 783
Aldosterone antagonists, for heart failure, 869–870, 872
AliveCor Heart Monitor, 888
ALTITUDE survival study, 881
Ambulatory electrocardiography, 878
American College of Cardiology
   cardiovascular disease risk prediction tools of, 717, 719, 721–728
   chest pain guidelines of, 842–844
   TAVR guidelines of, 806–811
American Heart Association
   cardiovascular disease risk prediction tools of, 717, 719, 721–728
   chest pain guidelines of, 842–844
   TAVR guidelines of, 806–811
Amiodarone, for atrial fibrillation, 785, 787
Amlodipine, for hypertension, 735
AMPLIFY (Oral Apixaban for the Treatment of Acute Venous Thromboembolism), 774–775
Amyloidosis, orthostatic hypotension in, 698–699
Angina, 836–838, 842–844
Angiography
   for TAVR, 811
   magnetic resonance, 854–855
Angiotensin receptor blockers
   for heart failure, 869–870
   for high blood pressure, 734–737
Angiotensin-converting enzyme inhibitors
   for heart failure, 869–870, 872
   for high blood pressure, 734–737
Antiarrhythmic drugs, for atrial fibrillation, 785–788
Anticoagulants. See also Novel oral anticoagulants.
   for atrial fibrillation, 782–786
   for mitral regurgitation, 748–749
Antidotes, to novel oral anticoagulants, 771–772
Antihypertensive drugs, guidelines for, 733–738
Aortenklappenregister score, for TAVR, 806
Aortic dissection, 841–842
Aortic regurgitation, 744–746
Aortic stenosis, 739–744
   burden of, 805–806
   transcatheter valve replacement for, 805–833
APEX (Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study), 765, 774–775
Apixaban
   drug interactions of, 763
   for atrial fibrillation, 782–783
   monitoring with, 764–765
   pharmacology of, 761–763
   switching of, 769
   trials with, 765–768, 774–775
Apixaban for the Prevention of Stroke in Subjects with Atrial Fibrillation (ARISTOTLE), 765–768
Apixaban Versus Acetylsalicylic Acid to Prevent Stroke Study, 782
Apps, for telemonitoring, 888
ARISTOTLE (Apixaban for the Prevention of Stroke in Subjects with Atrial Fibrillation), 765–768
Arrhythmias. See also Atrial fibrillation.
   devices for, 795–804
   remote monitoring of, 877–896
   syncope in, 699
Aspirin, for atrial fibrillation, 782
Atenolol, for hypertension, 735
Atherosclerotic cardiovascular disease, 711–731
   clinical guidelines for, 718–729
   hallmarks of, 712
   incidence of, 711
   pathophysiology of, 712–713
   risk assessment systems/scores for, 715–718
   risk factors for, 712, 714–715
Atrial appendage occlusion, for atrial fibrillation, 783
Atrial fibrillation
   in mitral regurgitation, 748
   incidence of, 781
   management of, 781–794
      ablation for, 771, 788–792
      novel oral anticoagulants for, 759–780
      pacemakers for, 798–799
      rate control in, 783–784
      rhythm control in, 784–792
      thromboembolism prevention in, 782–783
recurrence of, 789–791
remote monitoring of, 888
risk factors for, 781
silent, 791
Atrial flutter, in atrial fibrillation, 786, 788
Atrial tachycardias, after atrial fibrillation ablation, 790
Atrioesophageal fistula, in atrial fibrillation ablation, 790
Atrioventricular block, pacemakers for, 797–798
Austin-Flint murmur, 745
Automatic alert report, from pacemaker, 886
Autonomic dysfunction, syncope in, 691–710
Autotrigger event recorder, 878
AVERROES trial, 765, 768

B
Balloon ablation, for atrial fibrillation, 791–792
Balloon expandable valves, for TAVR, 811–812, 817–818, 822–829
Balloon mitral valvotomy, 748–749
Bendroflumethiazide, for hypertension, 735
Bernoulli equation, in echocardiography, 742
Beta-blockers
  for atrial fibrillation, 783–784
  for heart failure, 868–870, 872
  for hypertension, 735
Betrixaban
  drug interactions of, 763
  pharmacology of, 762–763
  trials with, 765, 774–775
Bisoprolol, for heart failure, 869–870
Biventricular Pacing for AV Block and Systolic Dysfunction (BLOCK HF), 790
Bleeding, with novel oral anticoagulants, 771
BLOCK HF (Biventricular Pacing for AV Block and Systolic Dysfunction), 790
Blood pressure monitoring, remote, 887–888
Bradycardia, pacemakers for, 796–799

C
Calcification, of aortic valve, 739–744
Calcium channel blockers
  for atrial fibrillation, 783–784
  for high blood pressure, 734–737
Canadian Cholesterol Guidelines, 717
Canadian Society guidelines, 726–727
Candesartan
  for heart failure, 870
  for hypertension, 735
Captopril
  for heart failure, 869–870
  for hypertension, 735
Cardiac catheterization
Cardiac (continued)
   for aortic stenosis, 743
   for TAVR, 811
Cardiac output, low
   in heart failure, 866
   syncope in, 693–695
Cardiac resynchronization, 801–802
   for atrioventricular block, 798
   for heart failure, 872
   for mitral regurgitation, 753
Cardiac syncope, 699
Cardiac tamponade, in atrial fibrillation ablation, 790
CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NHHA Class II Heart Failure Patients (CHAMPION) trial, 887
Cardiomyopathy
   hypertrophic, implantable cardioverter-defibrillator for, 801
   MRI for, 855–857
Cardiovascular disease
   anticoagulants for, 759–780
   aortic valve, 739–757, 805–833
   arrhythmia management devices for, 795–804
   atrial fibrillation in. See Atrial fibrillation.
   chest pain evaluation in, 835–837
   digital technology for, 877–896
   heart failure. See Heart failure.
   high blood pressure, 733–738
   magnetic resonance imaging for, 704, 742, 849–861
   mitral valve, 739–757, 809
   prevention of, 711–731
   risk assessment for, 711–731
   syncope in. See Syncope.
Cardioversion
   anticoagulants with, 772
   for atrial fibrillation, 784–785
Cardioverter-defibrillator
   for heart failure, 872, 874
   implantable, 799–801
Carotid sinus massage, 702
Carotid sinus syndrome, 696
Carotid ultrasound, for syncope, 704
Carvedilol
   for heart failure, 869–870
   for hypertension, 736
Cataplexy, 700–701
Catheter ablation, for atrial fibrillation, 788–792
Cell phones, for telemonitoring, 888 for
Cerebral perfusion, inadequate, syncope in, 693–695
CHA2D-52-VASc scoring system, for thromboembolic risk assessment, 782
CHAMPION (CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NHHA Class II Heart Failure Patients) trial, 887
Chest pain, in acute coronary syndrome, 835–847
Chlorthalidione, for hypertension, 735
Cholesterol Treatment Trialists Collaboration, 716
Chronicle Offers Management to Patients with Advanced Signs and Symptoms of Heart Failure (COMPASS-HF), 885–886
Cine imaging, in MRI, 851, 855
Circulatory support, for heart failure, 871
Circumferential ablation, for atrial fibrillation, 791–792
Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision (CONNECT) trial, 881
Clinical guidelines, for atherosclerotic cardiovascular disease, 718–729
Clonidine, for hypertension, 736
Coagulation assays, for anticoagulants, 764–765
COMPANION (Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure), 802
COMPaRative follow-up Schedule (COMPAS), 881
Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION), 802
COMPAS (COMPaRative follow-up Schedule), 881
COMPASS-HF (Chronicle Offers Management to Patients with Advanced Signs and Symptoms of Heart Failure), 885–886
Comprehensive Assessment of Frailty, for TAVR, 809
Computed tomography
  for syncope, 704
  for TAVR, 811
  for valvular heart disease, 742
Conduction disorders
  after TAVR, 828
  pacemakers for, 797, 799
Congenital heart disease, MRI for, 858
CONNECT (Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision) trial, 881
Consciousness, transient loss of, 692. See also Syncope.
Contrast agents, for MRI, 859
Core valves, for TAVR, 811–812, 817–822
Coronary artery disease
  chest pain evaluation in, 835–847
  TAVR risks in, 809
Corrigan pulse, 745
Cough syncope, 696
Cox-Maze procedure, for atrial fibrillation, 793
C-reactive protein, as cardiovascular risk factor, 718
Cryoballoon ablation, for atrial fibrillation, 791–792

D
Dabigatran
  bleeding complications with, 771
  drug interactions of, 763
  for atrial fibrillation, 783
  for cardioversion, 772
  in kidney failure, 774
Dabigatran (continued)
- monitoring with, 764–765
- pharmacology of, 760–763
- switching between, 769–770
- switching of, 769
- trials with, 765–768, 774–775
Dartmouth Atlas of Cardiovascular Care, 718–719
de Musset sign, 745
Deep vein thrombosis prevention, novel oral anticoagulants for, 774–776
Defecation syncope, 696
Defibrillators, remote monitoring of, 880–887
Diabetes mellitus
- as cardiovascular risk factor, 718
- in high blood pressure treatment with, 734
- orthostatic hypotension in, 698
Diamond score, 844
Digital technology, for monitoring, 877–896
Digoxin
- for atrial fibrillation, 783–784
- for heart failure, 869
Diltiazem, for hypertension, 735
Diluted thrombin time, for anticoagulants, 764–765
Direct aortic approach, for TAVR, 813–814, 816–817
Direct current cardioversion, for atrial fibrillation, 785
Direct Flow aortic valve, 829
Direct thrombin inhibitor, for anticoagulants, 764–765
Distal axillary approach, for TAVR, 814, 817–818
Diuretics, for heart failure, 867
Dizziness, remote monitoring of, 882–883
Dobutamine, for heart failure, 871
Dofetilide, for atrial fibrillation, 785, 787
Dronedarone, for atrial fibrillation, 786–787
Drop attacks, 700–701
Droxidopa, for orthostatic hypotension, 706
Drugs, orthostatic hypotension due to, 698
Duroziez sign, 745
Dyslipidemia, as risk factor, 712–729
Dyspnea, in heart failure, 866

E
Ecarin coagulation time, for anticoagulants, 764–765
Echocardiography
- for TAVR, 811
- for valvular heart disease, 741–742, 745, 748, 752–753
Edema, in heart failure, 866
Edoxaban
- drug interactions of, 763
- monitoring with, 764–765
- pharmacology of, 762–763
- trials with, 774–775
Edwards valves, for TAVR, 811–812
Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism (RE-COVER), 774–775
Eighth Joint National Committee guidelines for 2014, for high blood pressure management, 733–738
EINSTEIN-DVT (Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients with Acute Symptomatic Deep Vein Thrombosis), 774–775
EINSTEIN-PE (Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients with Acute Symptomatic Pulmonary Embolism), 774–775
Electrocardiography
  ambulatory, 878
  for acute coronary syndrome, 840–842
  for heart failure, 866
  for syncope, 699, 702
  for valvular heart disease, 745
Electroencephalography, for syncope, 704
Electrophysiology study, for syncope, 702
Enalapril
  for heart failure, 869–870
  for hypertension, 735
End-of-life care, for heart failure, 873–874
ENGAGE TIMI-AF (Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients with Atrial Fibrillation), 765–769
Engager valve, 829
Eplerenone, for heart failure, 869–870
Eprosartan, for hypertension, 735
Ethnicity
  as cardiovascular risk factor, 716
  in high blood pressure treatment, 734
Euro Heart Survey, 839
European Atherosclerosis Society guidelines, 726–727
European Society of Cardiology, 724
EuroSCORE (Logistic European system for Cardiac Operative Risk Evaluation), 806
Evidence-based medicine, for cardiovascular disease, 720–721
Exercise testing
  for aortic stenosis, 743
  for syncope, 702
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion (X-veRT), 772
EXPLORE Xa study, 765, 769
External event recorder, 878

F
Factor Xa inhibitor, clinical trials with, 769
Family history, as cardiovascular risk factor, 716
Fatigue, in heart failure, 866
Flecainide, for atrial fibrillation, 785, 787
Fludrocortisone, for orthostatic hypotension, 707
Fluid therapy, for orthostatic hypotension, 706–707
Foreign bodies, metallic, MRI with, 858–859
Fosinopril, for heart failure, 870
Frailty, assessment of, for TAVR, 807–811
Framingham Heart Study, 712, 714, 717, 722–723
Friedewald formula, 718
Furosemide, for hypertension, 736

G
Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing, With Warfarin in Patients with Atrial Fibrillation (ENGAGE TIMI-AF), 765–769
Glucose monitoring, remote, 887–888
GrandCare Systems, 888
Guidance of mobile Medical Applications, 889

H
Heart block, pacemakers for, 797–798
Heart cards, 878–879
Heart failure, 863–875
  acute, 866–871
  advanced stage of, 873
  cardiac resynchronization for, 801–802
  chronic, 871–874
  etiology of, 863–865, 872
  in mitral regurgitation, 753
  in sinus node dysfunction, 796
  remote monitoring for, 877–896
Heart Rhythm Society, 881
Heart Team approach, for TAVR, 806–811
Hematomas, after atrial fibrillation ablation, 790
Heparin, switching of, 769
High blood pressure, management guidelines for, guidelines for, 733–738
Hill sign, 745
HLT valve, 829
HOKUSAI VTE study, 774–775
Holter monitoring, 878
Hospice, for heart failure, 873–874
Hydralazine
  for heart failure, 869–870
  for hypertension, 736
Hydrochlorothiazide, for hypertension, 735
Hypersensitive carotid sinus syndrome, pacemakers for, 799
Hypertension
  as cardiovascular risk factor, 716
  management guidelines for, 733–738
Hypertrophic cardiomyopathy, 801, 856
Hypotension, orthostatic, 696–699, 706–707, 799
Ibutilide, for atrial fibrillation, 785
Implantable cardioverter-defibrillator, 799–801
  for heart failure, 872
  remote monitoring of, 880–887
Implantable loop recorder, 878
Implantable sensors, for remote monitoring, 885–887
Implanted devices, MRI with, 858–859
Indapamide, for hypertension, 735
Infective endocarditis, of aortic valve, 746
Inotropes, for heart failure, 870–871
Inovare valve, 829
Institute of Medicine, cardiovascular disease guidelines of, 719
INTERHEART study, 712
Internal loop recorders, 879, 881
International normalized ratio, for anticoagulants, 764–765
Internet Tracking Registry of Acute Coronary Syndrome registry, 837–839
Intolerance, orthostatic, 696–699
Irbesartan, for hypertension, 735
Ischemic heart disease, MRI for, 857
Isosorbide dinitrate, for heart failure, 870

J
JenaClip valve, 829
Joint National Committee guidelines for 2014, for high blood pressure management, 733–738
Jugular venous pressure, in heart failure, 866

K
Kidney disease
  in high blood pressure treatment with, 737
  TAVR risks in, 809
Kidney failure, novel oral anticoagulants in, 773

L
LAPTOP-HF (Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy), 885, 887
Left ventricular dysfunction, heart failure in, 863–865
LES (Logistic European system for Cardiac Operative Risk Evaluation), 806
Lewy-body dementia, orthostatic hypotension in, 698
Lifestyle interventions
  for atherosclerotic cardiovascular disease prevention, 714
  for orthostatic hypotension, 706–707
Lipoproteins, in cardiovascular disease risk assessment, 712–729
Lisinopril
  for heart failure, 869–870
  for hypertension, 735
Logistic European system for Cardiac Operative Risk Evaluation (EuroSCORE), 806
Long QT syndrome, pacemakers for, 799
Losaratan
  for heart failure, 870
  for hypertension, 735
Lotus valve, for TAVR, 827, 829
Lumos-T Safely Reduces Routine Office Device Follow-Up (TRUST)8, 881
LumReveal LINQ Insertable Cardiac Monitor, 879–880, 884
Lung disease, TAVR risks in, 809
Lyme disease, heart block in, 797

M

MADIT (Multicenter Automatic Defibrillator Implantation Trial), 800–802
Magnetic resonance imaging, 849–861
  applications of, 851–855
  for syncope, 704
  for valvular heart disease, 742
  image acquisition in, 850–851
  indications for, 855–858
  safety of, 858–859
Malignancy, novel oral anticoagulants in, 773
Masses, cardiac, MRI for, 857
Mechanical circulatory support, for heart failure, 871
Metabolic syndrome, as cardiovascular risk factor, 718
Metalazone, for heart failure, 867
Metoprolol
  for heart failure, 869–870
  for hypertension, 735
Micturition syncope, 696
Midodrine, for orthostatic hypotension, 706–707
Milrinone, for heart failure, 871
Mitral regurgitation, 749–753, 809
Mitral stenosis, 746–749
Mobile cardiac outpatient telemetry, 878–879, 882–883
MONICA/KORA Myocardial Infarction Registry, 839
Monitoring, remote, 877–896
MRI. See Magnetic resonance imaging.
Multicenter Automatic Defibrillator Implantation Trial (MADIT), 800–802
Multidimensional Geriatric Assessment, for TAVR, 809
Multiple-system atrophy, orthostatic hypotension in, 697
Myocardial infarction
  evaluation of, 835–847
  implantable cardioverter-defibrillator for, 800–801
  syncope in, 699
Myocarditis, MRI for, 856

N

National Cholesterol Education Adult Treatment Panel, 718, 720, 722
National Heart Act of 1948, 712
National Heart Institute, guidelines of, 712
National Heart, Lung, and Blood Institute, 722
National Institutes of Health, cardiovascular disease guidelines of, 719
National Lipid Association guidelines, 722–725, 728
Natriuretic peptides
  in aortic stenosis, 743
  in heart failure, 867
Nesiritide, for heart failure, 868
Neurocardiogenic syndromes, pacemakers for, 799
New York Heart Association, functional classification, 872
Nitinol-based self-expandable stent-mounted valves, for TAVR, 811–812, 817–818
Nitrites, for heart failure, 869–870
Nitrendipine, for hypertension, 735
Nitroglycerin, for heart failure, 868
Novel oral anticoagulants, 759–780
  advantages of, 759–760
  antidotes for, 770–771
  bleeding management with, 770
  clinical considerations with, 769–772
  disadvantages of, 759–760
  errors with, 770, 772
  for atrial fibrillation ablation, 771
  for cardioversion, 772
  for deep vein thrombosis prevention, 774–776
  history of, 759–760
  in kidney failure, 773
  in malignancy, 773
  monitoring with, 764–765
  pharmacology of, 760–764
  reversal of, 770
  surgery and, 771
  switching between, 769–770
  trials on, 765–769
Nuvant MTC, 879

O
Oral Apixaban for the Treatment of Acute Venous Thromboembolism (AMPLIFY), 774–775
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients with Acute Symptomatic Deep Vein
Thrombosis (EINSTEIN-DVT), 774–775
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients with Acute Symptomatic Pulmonary
Embolism (EINSTEIN-PE), 774–775
Orthostatic hypotension, 696–699, 706–707, 799

P
Pacemaker Remote Follow-up Evaluation and Review (PREFER), 881
Pacemakers, 796–799
  for atrial fibrillation, 791
  remote monitoring of, 880–887
Palliative care, for heart failure, 873–874
Palpitations, remote monitoring of, 882–883
PARAGON study, 841
Paravalvular regurgitation, after TAVR, 828
Parkinson disease, orthostatic hypotension in, 697
PARTNER (Placement of Aortic Transcatheter Valve) trial, 822–826
Patch monitor, 884
Pericardial disorders, 841, 858
Perindopril, for heart failure, 870
Phrenic nerve injury, after atrial fibrillation ablation, 790
Placement of Aortic Transcatheter Valve (PARTNER) trial, 822–826
Pooled Cohort Equations, 722
Postural hypotension, 696–699, 706–707, 799
Postural tachycardia syndrome, 699
Potassium channel blockers, for atrial fibrillation, 785–788
Predicted Risk of Mortality, for TAVR, 806
PREFER (Pacemaker Remote Follow-up Evaluation and Review), 881
Pregnancy, MRI in, 859
Pressure sensors, remote monitoring of, 880–887
Prevention, of atherosclerotic cardiovascular disease, 711–731
Primary autonomic nervous system failure, 697–699
PROCAM cardiovascular disease risk predictor, 717
PROM (Society of Thoracic Surgeons Predicted Risk of Mortality), for TAVR, 806
Propafenone, for atrial fibrillation, 785, 787
Proteus Digital, medication adherence tool of, 888
Prothrombin time, for anticoagulants, 764–765
Pseudoaneurysms, after atrial fibrillation ablation, 790
Pulmonary embolism, 774–776, 841
Pulmonary veins, atrial fibrillation foci in, 788–792
Pure autonomic failure, orthostatic hypotension in, 698

Q
QRS complex, alterations of, cardiac resynchronization for, 801–802
Quinapril, for heart failure, 870
Quincke pulse, 745

R
Radiography, for heart failure, 866
Ramipril, for heart failure, 870
Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etxilate, 765–768, 772
Rate control, for atrial fibrillation, 783–784
RE-COVER (Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism), 774–775
Reflex syncope, 695–696, 706
RE-LY (Randomized Evaluation of Long Term Anticoagulant Therapy) With Dabigatran Etxilate, 772
Remote monitoring technology
  for cardiac rhythm, 878–880
  for comorbid conditions, 887–888
  for rhythm control devices, 880–887
REPRISE (REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System: Evaluation of Safety and Performance) study, 827
Reynolds Risk Score, for cardiovascular disease, 717
Rhythm control, for atrial fibrillation, 784–792
Right ventricle, MRI of, 857
Right ventricular pacing, 798
Risk assessment systems/scores, for atherosclerotic cardiovascular disease, 715–718
Rivaroxaban
  drug interactions of, 763
  for atrial fibrillation, 783
  in kidney failure, 774
  monitoring with, 764–765
  pharmacology of, 761–763
  switching of, 769
  trials with, 765–768, 772, 774–775
ROCKET AF (Rivaroxaban versus Warfarin in Non-valvular Atrial Fibrillation), 765–768

S
Salt intake
  in orthostatic hypotension, 706–707
  in syncope, 706
Sapien valves, for TAVR, 811–812
Sarcoidosis, pacemakers for, 799
SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial), 801
SEEQ monitor, 879
Seizures, syncope in, 699
Shy-Drager syndrome, orthostatic hypotension in, 697
Sinus node dysfunction, pacemakers for, 796–797
Situational syncope, 696, 706
SJM Confirm Implantable Cardiac Monitor, 879
Smart phones, for telemonitoring, 888
Smoking, as cardiovascular risk factor, 716
Society of Thoracic Surgeons Predicted Risk of Mortality (PROM)S, for TAVR, 806
Sodium channel blockers, for atrial fibrillation, 785–788
Sodium nitroprusside, for heart failure, 868
Sotalol, for atrial fibrillation, 788
SOURCE trial, 823
Spironolactone
  for heart failure, 867, 869–870
  for hypertension, 736
Stable angina, 836–838
Statins, for atherosclerotic cardiovascular disease, guidelines for, 714–715, 722–729
STEMI and STEMI equivalent, 835–836, 840–842
Stress test, 844
Stroke
  after TAVR, 828
  in atrial fibrillation ablation, 790
  prevention of, in atrial fibrillation, 782–783
Subclavian artery approach, for TAVR, 814, 817
Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), 801
Sudden death
  in sinus node dysfunction, 796–797
  prevention of, implantable cardioverter-defibrillator for, 800–801
Sudomotor testing, for syncope, 705
Supine hypertension, in orthostatic hypertension treatment, 707
Surgery, with novel oral anticoagulants, 771
SURTAVI (SUrgical Replacement and Transcatheter Aortic Valve Implantation) trial, 825–827
Sympathetic sdrenergic function testing, for syncope, 705
Syncope
  in autonomic dysfunction, 691–710
  ancillary testing for, 703–704
  autonomic nervous system testing for, 704–707
  cardiac, 699
  causes of, 701
  evaluation of, 699–701
  history in, 702
  orthostatic hypotension, 696–699
  pathophysiology of, 693–695
  physical examination for, 702–703
  prodromal symptoms of, 595–596
  reflex, 695–696, 706
  treatment of, 706–707
  in sinus node dysfunction, 796
  neurocardiogenic, 799
  remote monitoring of, 882–883
Systolic dysfunction, TAVR risks in, 809

T
Tachyarrhythmias, syncope in, 699
Tachycardia-bradycardia syndrome, 783
TAVR. See Transcatheter aortic valve replacement.
Telephone-based monitoring, 887–888
TEN-HMS (Trans-European Network-Home-Care Management System) study, 888
Text messaging, for telemonitoring, 888
Thiazide diuretics, for high blood pressure, 734–737
Thromboembolism, prevention of, in atrial fibrillation, 782–783
Tilt table testing, for syncope, 702
Tissue characterization, in MRI, 853–854
Trandolapril, for heart failure, 870
Transapical approach, for TAVR, 813, 815
Transcatheter aortic valve replacement, 805–833
  approaches for, 813–817
  contraindications to, 805–812
  indications for, 805–812, 828, 830
  outcomes of, 817–828
  patient selection for, 806–811
  platforms for, 811–812
  rationale for, 805–806
  risk assessment for, 806–811
techniques for, 813–817
Trans-European Network-Home-Care Management System (TEN-HMS) study, 888
Transfemoral approach, for TAVR, 813
Transient loss of consciouses, 692. See also Syncope.
Triggers, avoidance of, for syncope, 706
Troponin elevation
  causes of, 838–839, 842
  in heart failure, 867
TRUST (Lumos-T Safely Reduces Routine Office Device Follow-Up), 881

U
Ultrasoundography, for syncope, 704
Unstable angina, 836–838

V
Valsalva maneuver, for syncope testing, 704–705
Valsartan
  for heart failure, 870
  for hypertension, 735
Valve repair, for mitral regurgitation, 752–753
Valve replacement
  for aortic stenosis, 746
  for mitral regurgitation, 752–753
Valvular heart disease, 739–757. See also specific valves.
  aortic regurgitation, 744–746
  aortic stenosis, 739–744
  mitral regurgitation, 749–753
  mitral stenosis, 746–749
  MRI for, 858
Vascular complications, after TAVR, 828
Vasodilators, for heart failure, 867–868
Vasovagal syncope, 695–696
Venous pooling, in syncope, 696
Ventricular assist devices, for heart failure, 871
Ventricular noncompaction, 857
VENTURE-AF study, 771
Vital signs, in heart failure, 866
Volume status, in heart failure, 872
Vulnerable plaque theory, in coronary artery disease, 837

W
Warfarin
  alternatives to, 759
  for atrial fibrillation, 782
WATCHMAN device, for atrial fibrillation, 783
Wolff-Parkinson-White syndrome, atrial fibrillation in, 784
X

X-veRT (Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion), 772